Barclays analyst Gena Wang lowered the firm’s price target on Ionis Pharmaceuticals to $40 from $44 and keeps an Equal Weight rating on the shares. The analyst continues to see a balanced risk/reward in near term post the Q4 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IONS:
- Ionis Pharmaceuticals sees FY23 revenue $575M, consensus $672.18M
- Ionis Pharmaceuticals reports Q4 EPS (37c), consensus (92c)
- Ionis reports fourth quarter and full year 2022 financial results
- Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development
- Ionis Pharmaceuticals receives FDA Fast Track designation for olezarsen
